Business Context and Reporting Period
This Form 8-K, dated February 25, 2026, reports significant corporate governance changes for The Cigna Group. The filing announces the appointment of a new Chief Executive Officer (CEO) and updates to the Board of Directors' composition and leadership structure, effective July 1, 2026, with certain board changes effective April 1, 2026.
Key Financial Metrics and Guidance
The filing does not report historical revenue, profit, cash flow, or debt figures for a specific reporting period. However, it reaffirms the company's forward-looking financial guidance for the full year 2026:
- Consolidated Adjusted Income from Operations: At least $30.25 per share.
- Evernorth Pre-Tax Adjusted Income from Operations: At least $6.9 billion.
- Cigna Healthcare Pre-Tax Adjusted Income from Operations: At least $4.5 billion.
Management notes that adjusted income from operations excludes net investment gains/losses, amortization of acquired intangible assets, and special items. A reconciliation to GAAP net income is not provided for forward-looking periods due to uncertainty regarding future investment results and special items.
Material Changes and Executive Compensation
The primary material change is the CEO succession plan. Mr. Brian C. Evanko, currently President and COO, will succeed Mr. David M. Cordani as CEO effective July 1, 2026. Mr. Cordani will retire as CEO and assume the role of Executive Chair of the Board.
Compensation arrangements approved for the new roles include:
- Mr. Evanko (CEO): Base salary of $1.3 million; Enterprise Incentive Plan (EIP) target of $2.6 million; Long-Term Incentive (LTI) target of $15.1 million. Additionally, a one-time Transitional Equity Award with a target value of $3.5 million was approved.
- Mr. Cordani (Executive Chair): Base salary of $1.0 million; EIP target of $2.0 million. He remains eligible for LTI awards, with specific provisions for the vesting of his 2026-2028 Strategic Performance Shares.
Board Leadership and Committee Changes
Effective April 1, 2026, the Board size increased to twelve members. Key leadership changes include:
- Lead Independent Director: Mr. Eric J. Foss succeeds Mr. Eric C. Wiseman.
- Corporate Governance Committee Chair: Mr. Eric C. Wiseman transitions to this role.
- Committee Composition: Updates were made to the Audit & Compliance, Corporate Governance, Finance & Technology, and People Resources committees to reflect the new leadership structure.
Risks and Contingencies
The filing includes a cautionary note regarding forward-looking statements, highlighting risks that could cause actual results to differ materially from projections. Key risks include:
- Healthcare cost management, price competition, and inflation pressures.
- Changes in drug pricing, pharmacy provider markets, and relationships with pharmaceutical manufacturers.
- Regulatory changes, government program participation uncertainties, and compliance costs.
- Cybersecurity threats, data privacy issues, and reliance on third-party systems.
- Macroeconomic conditions, including recession risks and interest rate changes.
- Integration challenges related to strategic transactions.
Investor Verification Checklist
- Verify the exact effective dates for the CEO transition (July 1, 2026) and Board changes (April 1, 2026).
- Review the specific performance metrics tied to Mr. Evanko's Strategic Performance Shares (SPS) to understand payout conditions.
- Confirm the definition of "Adjusted Income from Operations" used in the guidance to ensure comparability with GAAP metrics in future earnings reports.
- Monitor the company's ability to meet the reaffirmed 2026 segment targets for Evernorth and Cigna Healthcare amidst the leadership transition.
- Check for any subsequent filings regarding the vesting terms of Mr. Cordani's transitional equity awards.